- Home
- RGNX vs AQST Comparison
RGNX vs AQST Comparison
Compare RGNX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGNX | AQST |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 761.9M | 707.6M |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RGNX | AQST |
|---|---|---|
| Price | $8.03 | $3.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $29.13 | $8.83 |
| AVG Volume (30 Days) | 1.2M | ★ 6.6M |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $161,318,000.00 | $43,397,000.00 |
| Revenue This Year | $128.55 | N/A |
| Revenue Next Year | $47.33 | $17.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 91.30 | N/A |
| 52 Week Low | $5.04 | $2.12 |
| 52 Week High | $16.19 | $7.55 |
Technical Indicators
Market Signals| Indicator | RGNX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 24.36 | 45.02 |
| Support Level | $10.15 | $3.61 |
| Resistance Level | $8.63 | $4.18 |
| Average True Range (ATR) | 0.79 | 0.26 |
| MACD | -0.35 | 0.10 |
| Stochastic Oscillator | 6.92 | 59.66 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.